Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    DAR GLOBAL EXPANDS SAUDI ARABIA PORTFOLIO WITH NEW JEDDAH DEVELOPMENT VALUED AT SAR 1 BILLION

    November 16, 2026

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026
    Middle East NewsreportMiddle East Newsreport
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Middle East NewsreportMiddle East Newsreport
    Home » Innovative Immunology Biotech Windward Bio Lists on Nasdaq
    PR Newswire

    Innovative Immunology Biotech Windward Bio Lists on Nasdaq

    November 14, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    SHANGHAI, Nov. 14, 2026 /PRNewswire/ — Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners’ 11th IPO in 2026.

    Qiming Venture Partners invested in Windward Bio’s inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.

    Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

    Windward Bio’s lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company’s pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases. Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed, and has separately licensed WIN027 from Qyuns Therapeutics.

    “Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies this approach. We believe novel, long-acting biologics will reshape the treatment of severe chronic respiratory and skin diseases, and that WIN378 and WIN027 have the potential to expand and meaningfully improve the treatment options available to patients. In the hands of Luca and his team, with their expertise and proven track record, Windward is well-positioned to deliver on this potential, and we look forward to supporting the company through its next phase of growth,” said Alexander Sinclair Wilson, Principal at Qiming Venture Partners.

    About Qiming Venture Partners

    Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

    Since our debut, we have backed over 630 fast-growing and innovative companies. Over 290 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 110 portfolio companies that have achieved unicorn or super unicorn status.

    Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.AI, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

    Cision View original content:https://www.prnewswire.co.uk/news-releases/innovative-immunology-biotech-windward-bio-lists-on-nasdaq-302939554.html

    Related Posts

    DAR GLOBAL EXPANDS SAUDI ARABIA PORTFOLIO WITH NEW JEDDAH DEVELOPMENT VALUED AT SAR 1 BILLION

    November 16, 2026

    ZTE Powers High Efficiency AIDC with Robust Energy Infrastructure

    November 16, 2026

    HONOR RANKS NO. 1 AMONG ANDROID SMARTPHONE BRANDS IN CHINA AS MAGIC9 SERIES SALES SURPASS 500,000 UNITS

    November 16, 2026

    Phoenix Contact Training Team Sets New Guinness World Record in Wiring

    November 16, 2026

    Keeper Family, Shaped Around You: Introducing Sungrow’s Comprehensive C&I Energy Storage Solutions

    November 16, 2026

    Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    November 16, 2026
    Last News

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    – Congo’s Ebola outbreak has passed 11,200 cases and 5,500 deaths and is still not under control six months after it was declared, Africa CDC said. Director-General Jean Kaseya warned on Sunday that it could become the worst Ebola outbreak

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026

    – Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, has held talks with Timor-Leste’s President José Ramos-Horta on expanding economic, trade, investment and renewable energy cooperation. Ramos-Horta is on a working visit to the UAE. The two leaders

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    – Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, has received Arab League Secretary-General Nabil Fahmy in Abu Dhabi to discuss regional developments. The talks focused on the challenges facing the Arab world and ways to strengthen joint

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    – The African Development Bank Group will provide Morocco with €434.4 million to back economic governance reforms and strengthen resilience to climate change. The financing agreement was signed in Rabat on November 13 and is worth nearly 4.8 billion dirhams.

    © 2026 Middle East Newsreport | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.